Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Drugs. 2020 Jun;80(9):915-922. doi: 10.1007/s40265-020-01326-8.
A regimen comprising extended release injectable suspensions of cabotegravir and rilpivirine for concurrent administration (CABENUVA™) is being developed by ViiV Healthcare and Janssen Pharmaceutica (Janssen) as a complete regimen for HIV infection. Based on the results of the ATLAS and FLAIR trials, the regimen was recently approved in Canada for the treatment of HIV-1 infection in adults to replace current antiretroviral therapy in patients who are virologically stable and suppressed. This article summarizes the milestones in the development of co-packaged cabotegravir and rilpivirine leading to this first approval.
一种包含卡替拉韦和利匹韦林的延长释放注射混悬剂的方案（CABENUVA）正在由 ViiV Healthcare 和杨森制药（Janssen）共同开发，作为一种针对 HIV 感染的完整方案。基于 ATLAS 和 FLAIR 试验的结果，该方案最近在加拿大获得批准，用于治疗成人 HIV-1 感染，以替代当前在病毒学上稳定和抑制的患者中的抗逆转录病毒治疗。本文总结了导致这一首次批准的共包装卡替拉韦和利匹韦林的开发里程碑。
